Which has preferable earnings and valuation, DWTX or EQ?

Equillium is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A Equillium N/A N/A -$22.40M -$0.32 N/A

Is DWTX or EQ more profitable?

Equillium's return on equity of -61.43% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -108.57% -30.28% Equillium N/A -61.43% -53.72%

Does the media favor DWTX or EQ?

In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 2 articles in the media. Equillium's average media sentiment score of 0.25 beat Dogwood Therapeutics' score of 0.00 indicating that Equillium is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Equillium 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DWTX or TNYA more profitable?

Tenaya Therapeutics' return on equity of -80.56% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -108.57% -30.28% Tenaya Therapeutics N/A -80.56% -65.21%

Does the media prefer DWTX or TNYA?

In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 2 articles in the media. Tenaya Therapeutics' average media sentiment score of 0.26 beat Dogwood Therapeutics' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenaya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, ADAG or DWTX?

Adagene has higher revenue and earnings than Dogwood Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 22.11 -$17.61M N/A N/A Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A

Is ADAG or DWTX more profitable?

Adagene's return on equity of 0.00% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Dogwood Therapeutics N/A -108.57% -30.28%

Does the media refer more to ADAG or DWTX?

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Adagene. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 1 mentions for Adagene. Adagene's average media sentiment score of 0.75 beat Dogwood Therapeutics' score of 0.00 indicating that Adagene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Dogwood Therapeutics (DWTX) Competitors

$1.46 +0.06 (+4.29%)

Closing price 04:00 PM Eastern

Extended Trading

$1.43 -0.03 (-1.99%)

As of 04:19 PM Eastern

Compare

DWTX vs. MDWD, ACOG, EQ, TNYA, and ADAG

Should you buy Dogwood Therapeutics stock or one of its competitors? MarketBeat compares Dogwood Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dogwood Therapeutics include MediWound (MDWD), Alpha Cognition (ACOG), Equillium (EQ), Tenaya Therapeutics (TNYA), and Adagene (ADAG). These companies are all part of the "pharmaceutical products" industry.

How does Dogwood Therapeutics compare to MediWound?

Dogwood Therapeutics (NASDAQ:DWTX) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

In the previous week, Dogwood Therapeutics had 2 more articles in the media than MediWound. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 0 mentions for MediWound. Dogwood Therapeutics' average media sentiment score of 0.00 equaled MediWound'saverage media sentiment score.

Company	Overall Sentiment
Dogwood Therapeutics	Neutral
MediWound	Neutral

MediWound has higher revenue and earnings than Dogwood Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
MediWound	$16.96M	10.93	-$23.88M	-$2.26	N/A

Dogwood Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 721.92%. MediWound has a consensus target price of $34.00, suggesting a potential upside of 135.78%. Given Dogwood Therapeutics' higher probable upside, equities research analysts plainly believe Dogwood Therapeutics is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Dogwood Therapeutics has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market. Comparatively, MediWound has a beta of 0.14, indicating that its share price is 86% less volatile than the broader market.

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dogwood Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -180.30%. MediWound's return on equity of -67.22% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
MediWound	-180.30%	-67.22%	-31.87%

Summary

MediWound beats Dogwood Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Alpha Cognition?

Dogwood Therapeutics (NASDAQ:DWTX) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Dogwood Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 721.92%. Alpha Cognition has a consensus target price of $16.00, suggesting a potential upside of 102.53%. Given Dogwood Therapeutics' higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Dogwood Therapeutics has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market.

In the previous week, Dogwood Therapeutics had 2 more articles in the media than Alpha Cognition. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 0 mentions for Alpha Cognition. Dogwood Therapeutics' average media sentiment score of 0.00 equaled Alpha Cognition'saverage media sentiment score.

Company	Overall Sentiment
Dogwood Therapeutics	Neutral
Alpha Cognition	Neutral

Alpha Cognition has higher revenue and earnings than Dogwood Therapeutics. Alpha Cognition is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Alpha Cognition	$10.83M	15.89	-$20.67M	-$1.35	N/A

9.1% of Dogwood Therapeutics shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by company insiders. Comparatively, 8.6% of Alpha Cognition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dogwood Therapeutics has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Alpha Cognition's return on equity of -58.35% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Alpha Cognition	-232.23%	-58.35%	-45.99%

Summary

Alpha Cognition beats Dogwood Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Equillium?

Dogwood Therapeutics (NASDAQ:DWTX) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Dogwood Therapeutics has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market. Comparatively, Equillium has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 2 articles in the media. Equillium's average media sentiment score of 0.25 beat Dogwood Therapeutics' score of 0.00 indicating that Equillium is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Equillium	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 27.0% of Equillium shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by insiders. Comparatively, 17.8% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Equillium's return on equity of -61.43% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Equillium	N/A	-61.43%	-53.72%

Equillium is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Equillium	N/A	N/A	-$22.40M	-$0.32	N/A

Dogwood Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 721.92%. Equillium has a consensus price target of $7.57, suggesting a potential upside of 174.33%. Given Dogwood Therapeutics' higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Equillium	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70

Summary

Equillium beats Dogwood Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Tenaya Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Dogwood Therapeutics has higher earnings, but lower revenue than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Tenaya Therapeutics	$225K	760.94	-$90.60M	-$0.47	N/A

Dogwood Therapeutics has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.83, suggesting that its stock price is 183% more volatile than the broader market.

In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 2 articles in the media. Tenaya Therapeutics' average media sentiment score of 0.26 beat Dogwood Therapeutics' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Dogwood Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 721.92%. Tenaya Therapeutics has a consensus target price of $4.00, indicating a potential upside of 406.97%. Given Dogwood Therapeutics' higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Tenaya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Tenaya Therapeutics' return on equity of -80.56% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

Summary

Tenaya Therapeutics beats Dogwood Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Adagene?

Adagene (NASDAQ:ADAG) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Adagene. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 1 mentions for Adagene. Adagene's average media sentiment score of 0.75 beat Dogwood Therapeutics' score of 0.00 indicating that Adagene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adagene has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market.

Adagene currently has a consensus target price of $8.00, indicating a potential upside of 123.46%. Dogwood Therapeutics has a consensus target price of $12.00, indicating a potential upside of 721.92%. Given Dogwood Therapeutics' higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Adagene has higher revenue and earnings than Dogwood Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	22.11	-$17.61M	N/A	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Adagene's return on equity of 0.00% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Dogwood Therapeutics	N/A	-108.57%	-30.28%

9.5% of Adagene shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 21.2% of Adagene shares are owned by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Adagene beats Dogwood Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Dogwood Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DWTX vs. The Competition

Export

Metric	Dogwood Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$49.10M	$3.64B	$6.77B	$12.60B
Dividend Yield	N/A	2.18%	2.67%	9.67%
P/E Ratio	-0.14	21.35	26.91	23.97
Price / Sales	N/A	174.30	507.72	91.38
Price / Cash	N/A	150.24	49.71	59.37
Price / Book	0.63	8.00	10.56	6.16
Net Income	-$34.26M	$23.81M	$3.60B	$331.71M
7 Day Performance	1.39%	-3.23%	-2.15%	-1.94%
1 Month Performance	-5.19%	-0.70%	0.11%	-2.49%
1 Year Performance	-68.87%	41.99%	22.63%	17.28%

Dogwood Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DWTX Dogwood Therapeutics	1.9264 of 5 stars	$1.46 +4.3%	$12.00 +721.9%	-70.9%	$49.10M	N/A	N/A	5	News Coverage High Trading Volume
MDWD MediWound	3.1738 of 5 stars	$14.25 flat	$34.00 +138.6%	-28.8%	$183.15M	$16.96M	N/A	80
ACOG Alpha Cognition	3.8997 of 5 stars	$8.05 -3.9%	$16.00 +98.8%	-20.9%	$182.47M	$10.22M	N/A	N/A	High Trading Volume
EQ Equillium	2.5027 of 5 stars	$2.76 -4.2%	$7.57 +174.3%	+535.1%	$182.09M	$41.10M	N/A	40	News Coverage
TNYA Tenaya Therapeutics	2.4738 of 5 stars	$0.86 +3.4%	$4.00 +362.6%	-3.7%	$181.52M	N/A	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DWTX) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dogwood Therapeutics (DWTX) Competitors

DWTX vs. MDWD, ACOG, EQ, TNYA, and ADAG

How does Dogwood Therapeutics compare to MediWound?

Summary

How does Dogwood Therapeutics compare to Alpha Cognition?

Summary

How does Dogwood Therapeutics compare to Equillium?

Summary

How does Dogwood Therapeutics compare to Tenaya Therapeutics?

Summary

How does Dogwood Therapeutics compare to Adagene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX vs. The Competition

Dogwood Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dogwood Therapeutics (DWTX) Competitors

DWTX vs. MDWD, ACOG, EQ, TNYA, and ADAG

How does Dogwood Therapeutics compare to MediWound?

Does the media prefer DWTX or MDWD?

Which has stronger valuation & earnings, DWTX or MDWD?

Do analysts rate DWTX or MDWD?

Which has more volatility and risk, DWTX or MDWD?

Do insiders and institutionals hold more shares of DWTX or MDWD?

Is DWTX or MDWD more profitable?

Summary

How does Dogwood Therapeutics compare to Alpha Cognition?

Do analysts prefer DWTX or ACOG?

Which has more volatility and risk, DWTX or ACOG?

Does the media favor DWTX or ACOG?

Which has higher valuation and earnings, DWTX or ACOG?

Do insiders & institutionals have more ownership in DWTX or ACOG?

Is DWTX or ACOG more profitable?

Summary

How does Dogwood Therapeutics compare to Equillium?

Which has more volatility and risk, DWTX or EQ?

Does the media favor DWTX or EQ?

Do insiders and institutionals have more ownership in DWTX or EQ?

Is DWTX or EQ more profitable?

Which has preferable earnings and valuation, DWTX or EQ?

Do analysts recommend DWTX or EQ?

Summary

How does Dogwood Therapeutics compare to Tenaya Therapeutics?

Which has better valuation & earnings, DWTX or TNYA?

Which has more risk and volatility, DWTX or TNYA?

Does the media prefer DWTX or TNYA?

Do insiders and institutionals have more ownership in DWTX or TNYA?

Do analysts prefer DWTX or TNYA?

Is DWTX or TNYA more profitable?

Summary

How does Dogwood Therapeutics compare to Adagene?

Does the media refer more to ADAG or DWTX?

Which has more volatility and risk, ADAG or DWTX?

Do analysts recommend ADAG or DWTX?

Which has stronger valuation & earnings, ADAG or DWTX?

Is ADAG or DWTX more profitable?

Do institutionals and insiders have more ownership in ADAG or DWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX vs. The Competition

Dogwood Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools